Vancomycin for the treatment of methicillin-resistant staphylococcal and enterococcal infections in 15 horses

Canadian Journal of Veterinary Research

Volumn 69, Issue 4, 2005, Pages 278-286

  Orsini, James A ^a   Snooks Parsons, Corinna ^a   Stine, Lynne ^a   Haddock, Marie ^a   Ramberg, Charles F ^a   Benson, Charles E ^a   Nunamaker, David M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; CEFTIOFUR; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; PENICILLIN G; PENICILLIN G POTASSIUM; POLY(METHYL METHACRYLATE); RIFAMPICIN; SUCRALFATE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIUM CULTURE; BONE INFECTION; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENTEROCOCCUS; HORSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; REVIEW; SOFT TISSUE INFECTION;

AMINOGLYCOSIDES; ANIMALS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HORSES; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; EQUIDAE; EQUUS CABALLUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCI;

EID: 28444488491     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Matzke GR, Zhael GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-282.
2. Chambers HF. Antimicrobial agents - protein synthesis inhibitors and miscellaneous antibacterial agents. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1262-1264.
3. Mascaretti OA. Inhibitors of peptidoglycan biosynthesis - bacitracin and glycopeptides. In: Bacteria versus Antibacterial Agents. Washington, DC: ASM Press, 2003:203-216.
4. Kernodle DS, Kaiser AB. Comparative prophylactic efficacy of cefazolin and vancomycin in guinea pig model of Staphylococcus aureus wound infection. J Infect Dis 1993;168:152-157.
5. Kernodle DS, Kaiser AB. Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection. Antimicrob Agents Chemother 1994;38:1325-1330.
6. Fantin B, Leclercq R, Duval J, Carbon C. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:2466-2469.
7. Hershberger E, Aeschlimann JR, Moldovan T, Rybak MJ. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrob Agents Chemother 1999;43:717-721.
8. Jackson MW, Panciera DL, Faye H. Administration of vancomycin for treatment of ascending bacterial cholangiohepatitis in a cat. J Am Vet Med Assoc 1994;204:602-605.
9. Boost M, Lai L, O'Donoghue M. Drug resistance in fecal enterococci in Hong Kong. J Infect Chemother 2004;10:326-330.
10. Mirovic V, Tomanovic B, Konstantinovic S. The frequency of resistance to antibiotics of most frequently isolated bacteria from blood cultures during the period 1997-2002 [translation from Serbian]. Vojnosanit Pregl 2004;61:391-397.
11. Lavoie SR, Wong ES, Coudron PE, Williams DS, Markowitz SM. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis. Antimicrob Agents Chemother 1993;37:1447-1451.
12. Hartmann FA, Trostle SS, Klohnen AAO. Isolation of a methicillin-resistant Staphylococcus aureus from a postoperative wound infection in a horse. J Am Vet Med Assoc 1997;211: 590-592.
13. Shimizu A, Kawano J, Yamamoto C, Kakutani O, Anzai T, Kamada M. Genetic analysis of equine methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis. J Vet Med Sci 1997;59:935-937.
14. Sequin JC, Walker RD, Caron JP, et al. Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission. J Clin Microbiol 1999;37:1459-1463.
15. Weese JS. Methicillin-resistant Staphylococcus aureus in horses and horse personnel. Vet Clin North Am Equine Pract 2004; 20:601-613.
16. Trostle SS, Peavey CL, King DS, Hartmann FA. Treatment of methicillin-resistant Staphylococcus epidermidis infection following repair of an ulnar fracture and humeroradial joint luxation in a horse. J Am Vet Med Assoc 2001;218:554-559,527.
17. Orsini JA, Ramberg CF Jr, Benson CE, Dreyfuss DJ, Vecchione JA, Kunz CC. Vancomycin kinetics in plasma and synovial fluid following intravenous administration in horses. J Vet Pharmacol Ther 1992;15:351-363.
18. Forbes BA, Sahm DF, Weissfeld AS. Laboratory cultivation and isolation of bacteria. In: Forbes BA, Sahm DF, Weissfeld AS, eds. Bailey and Scott's Diagnostic Microbiology. 10th ed. St Louis, Missouri: Mosby, 1998:150-166.
19. Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller FC, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press, 1999:264-282.
20. National Committee for Clinical Laboratory Standards. Approved Standard M31-A2. In: Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals. 2nd ed. NCCLS document M31-A2. National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania: The Committee, 2001.
21. Steer AC, Carapetis JR. Acute hematogenous osteomyelitis in children: recognition and management. Paediatr Drugs 2004; 6:333-346.
22. Paterson DL. Reduced susceptibility of Staphylococcus aureus to vancomycin: a review of current knowledge. Commun Dis Intell 1999;23:69-73.
23. Devriese LA, Ieven M, Goossens H, et al. Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob Agents Chemother 1996;40:2285-2287.
24. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357: 1179.
25. Hagman HM, Strausbaugh LJ. Vancomycin-resistant enterococcci. The "superbug" scourge that's coming your way. Postgrad Med 1996;99:60-65,69-71.
26. Klopp S. Resistance to vancomycin in US chicken feed. Lancet 1999;353:1190.
27. Ridwan B, Mascini E, van Der Reijden N, Verhoef J, Bonten M. What action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals? BMJ 2002;324: 666-668.
28. Slaughter S, Hayden MK, Nathan C, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococcci in a medical intensive care unit. Ann Intern Med 1996;125: 448-456.
29. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493-501.
30. Pfelz RF, Wilkinson BJ. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr Drug Targets Infect Disord 2004;4:273-294.
31. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 2004;32:315-327.
32. Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005;49:470-472.
33. Jensen KT, Schonheyder H, Gottschau A, Thomsen VF. Impact of the agar medium and disc type on disc infusion susceptibility testing against teicoplanin and vancomycin. APMIS 1994;102: 94-102.
34. Peloso JG, Cohen ND, Walker MA, Watkins JP, Gayle JM, Moyer W. Case-control study of risk factors for the development of laminitis in the contralateral limb in Equidae with unilateral lameness. J Am Vet Med Assoc 1996;209:1746-1749.
35. Redden RF. Preventing laminitis in the contralateral limb of horses with non-weight-bearing lameness. Proc Am Assoc Equine Pract 2003;49:320-327.
36. Rocha JL, Kondo W, Baptista MI, Da Cunha CA, Martins LT. Uncommon vancomycin-induced side effects. Braz J Infect Dis 2002;6:196-200.
37. Miner LJ, Faix RG. Large vancomycin overdose in two premature infants with minimal toxicity. Am J Perinatol 2004;21:433-438.
38. Kacew S, Bergeron MG. Pathogenic factors in aminoglycoside-induced nephrotoxicity. Toxicol Lett 1990;51:241-259.
39. Beauchamp D, Gourde P, Simard M, Bergeron MG. Subcellular localization of tobramycin and vancomycin given alone and in combination in proximal tubular cells, determined by immunogold labeling. Antimicrob Agents Chemother 1992;36:2204-2210.
40. Brummett RE. Ototoxicity of vancomycin and analogues. Otolaryngol Clin Am 1993;26:821-828.